Keyphrases
Cancer Risk
100%
Immune-mediated Inflammatory Diseases
100%
Pediatric Onset
100%
Immunomodulatory Drugs (IMiDs)
75%
Confidence Interval
50%
Anti-tumor Necrosis Factor (anti-TNF)
25%
Lymphoma
25%
Thiopurines
25%
High Risk
25%
Follow-up Time
12%
Immunomodulator
12%
Working Diagnosis
12%
Cancer Surveillance
12%
Adulthood
12%
Lymphoma Cancer
12%
Family Income
12%
Secondary Exposure
12%
Ulcerative Colitis
12%
Connective Tissue Disease
12%
Medical Treatment
12%
Skin Cancer Risk
12%
Skin Cancer
12%
Adult-onset
12%
Vasculitis
12%
Tumor Necrosis Factor Antagonist
12%
Anti-TNF Treatment
12%
Hazard Ratio
12%
Primary Sclerosing Cholangitis
12%
Autoimmune Hepatitis
12%
Systemic Juvenile Idiopathic Arthritis (sJIA)
12%
Systemic Lupus Erythematosus
12%
Individual-based
12%
Personalized Cancer Therapy
12%
Health Registers
12%
Crohn's Disease
12%
Medicine and Dentistry
Immunity
100%
Inflammatory Disorder
100%
Pediatrics
100%
Malignant Neoplasm
100%
Tumor Necrosis Factor
50%
Cancer Risk
50%
Skin Cancer
25%
Mercaptopurine
25%
Crohn's Disease
12%
Systemic Lupus Erythematosus
12%
Combination Therapy
12%
Juvenile Idiopathic Arthritis
12%
Immunotherapy
12%
Vasculitis
12%
Ulcerative Colitis
12%
Hazard Ratio
12%
Cancer Epidemiology
12%
Primary Sclerosing Cholangitis
12%
Autoimmune Hepatitis
12%
Immunomodulating Agent
12%
Connective Tissue Disease
12%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Disease
100%
Tumor Necrosis Factor
100%
Malignant Neoplasm
100%
Mercaptopurine
50%
Skin Cancer
50%
Ulcerative Colitis
25%
Connective Tissue Disease
25%
Vasculitis
25%
Immunomodulating Agent
25%
Primary Sclerosing Cholangitis
25%
Combination Therapy
25%
Juvenile Rheumatoid Arthritis
25%
Immunotherapy
25%
Systemic Lupus Erythematosus
25%
Cancer Epidemiology
25%
Crohn's Disease
25%
Autoimmune Hepatitis
25%